E

The value of BRAF targeted cancer therapies in lung and colorectal cancer

The role of basket trials in small cancer subsets will be important to defining what targeted therapies work well...

August 20, 2015
E

Oncolytic viruses – are they ready for prime time?

Oncolytic viruses are fast becoming a hot new area in cancer research but who are the players and where is this field going?

August 6, 2015
E

Will targeting NY-ESO-1 prime the immune system in cancer?

Exploring NY-ESO-1 as a valid target in sarcoma, multiple myeloma and metastatic melanoma...

August 3, 2015
E

BMS and Exelixis announce new renal cell cancer data

Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?

July 22, 2015
E

Novel Targets Podcast: Non-inflamed Tumours

Can we find new ways to target prostate cancer and other non-immunogenic tumours with immunotherapies? The answer may surprise...

July 21, 2015
E

Biotech Strategy questions answered on BRAF, MEK, immunotherapy, mirvetuximab soravtansine and venetoclax

This month's Biotech Strategy Blog mail bag.

July 17, 2015
E

AstraZeneca take a punt on immuno-oncology

Interview with Dr Rob Iannone of AstraZeneca on their IO pipeline

July 15, 2015
E

Has AZD9291 been filed for T790M+ lung cancer?

Clovis have started their rolling NDA for rociletinib in T790M-positive lung cancer - what about AstraZeneca's AZD9291?

July 6, 2015
E
Dr William Pao Roche

Do you need a CAR T Cell Therapy to be a Global Cancer Immunotherapy Company?

Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.

July 1, 2015
E

Future of Prostate Cancer Immunotherapy

ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.

June 29, 2015
E

ASCO 2015 Review of New Developments in Sarcoma

What's hot in soft tissue sarcomas at ASCO 2015? Find out more...

June 22, 2015
E

Biotech Strategy questions answered on neratinib, bavituximab, enzalutamide and more!

Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...

June 17, 2015
E

Checkpoint inhibitors show early promise in Small Cell Lung Cancer

We've heard a lot about checkpoint immunotherapies in non-small cell lung cancer (NSCLC), but what about it's deadlier cousin, small cell lung cancer (SCLC)? Find out more...

June 16, 2015
E

Beyond the Big Four in checkpoint blockade

Beyond the Big Four in checkpoint inhibitors, there is a raft of other companies anxious to get in the action. We take a look at Merck Serono and their progress with avelumab, an anti-PDL1 antibody

June 11, 2015
E

Combined checkpoint inhibition and chemotherapy – useful or not?

How do we help patients who are non-responders or have stable disease respond to checkpoint inhibitors? Will chemotherapy combos help or not?

June 8, 2015
E

Highlights of Day 4 at ASCO 2015 Annual Meeting

Highlights from Monday at the 2015 ASCO annual meeting in Chicago

June 1, 2015
E

ASCO 2015 Highlights of Day 3

What's hot on Plenary Sunday at ASCO 2015? We'll be updating this blog post during the day.

May 31, 2015
E

Highlights of ASCO 2015 Day 2 Live Blog

Highlights from Day 2 at ASCO 15 in Chicago

May 30, 2015
E

ASCO 2015 Cancer Immunotherapy – Reflections on Day 1

Reflections on data presented in the first cancer immunotherapy press briefing at ASCO 2015

May 30, 2015
E

Suicide Genes – what are they and are they really needed?

Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?

May 28, 2015
E

Targeting MYC – the undruggable protein – or is it?

Targeting MYC and bromodomains is an emerging area of research as we learn more about super enhancer transcription factor clusters around oncogenes that drive cancer.

May 26, 2015
E

New therapies for multiple myeloma may make an impact

Data at ASGCT and ASCO highlight potential new treatments in development for multiple myeloma

May 18, 2015
E

Highlights of ASCO15 Abstracts – Preview No 1

First in a series of previews of ASCO 2015 annual meeting abstracts.

May 13, 2015
E

Top 10 immunotherapy studies with checkpoint blockade at ASCO 2015

What are the hot checkpoint studies to watch out for at ASCO 2015? We created a cheat sheet to follow and track the data as tsunami hits...

May 8, 2015